Treatment Of Diabetes In Bullous Pemphigoid Patients: Where Do We Stand?

Treatment Of Diabetes In Bullous Pemphigoid Patients: Where Do We Stand?

Authors

  • Maria Alexandre Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal
  • Pedro Garrido Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal
  • Paulo Filipe Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal; Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; Dermatology Research Unit, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal

References

Chai ZT, Tan C, MeiQi Liau M, et al. Diabetes mellitus and hyperglycemic complications in bullous pemphigoid. J Am Acad Dermatol. 2020 May;82(5):1234-1237.

Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. Dermatol Pract Concept. 2020 Jun 29;10(3):e2020050.

Garrido PM, Alexandre MI, Travassos AR, Filipe P. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab. Dermatol Ther. 2020 Nov;33(6):e14160.

Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Aug;85(2):501-503.

Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Rep. 2021 Aug 5;15:107-109.

Lee H, Chung HJ, Pawar A, Patorno E, Kim DH. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea. JAMA Dermatol. 2020 Oct 1;156(10):1107-1114.

Downloads

Published

2023-01-31

Issue

2023 Vol 13, No 1 | January

Section

Commentary

License

Copyright (c) 2023 Maria Alexandre, Pedro Garrido, Paulo Filipe

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Alexandre M, Garrido P, Filipe P. Treatment Of Diabetes In Bullous Pemphigoid Patients: Where Do We Stand?. Dermatol Pract Concept. 2023;13(1):e2023063. doi:10.5826/dpc.1301a63

Share

Crossref
Scopus
Google Scholar
Europe PMC